Unknown PHASE1 INTERVENTIONAL 1-arm NCT02577458

Study of the Combination of CM082 With Everolimus in Patients With mRCC

Phase 1 Study of the Combination of CM082 With Everolimus in Patients With Metastatic Renal Cell Carcinoma (RCC): Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy

Sponsor: AnewPharma

Conditions Renal Cell Carcinoma Recurrent

Interventions CM082 Everolimus

Updated 7 times since 2017 Last updated: Jan 8, 2018 Started: Sep 30, 2015 Primary completion: Mar 31, 2018 Completion: Jun 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02577458, this PHASE1 trial focuses on Renal Cell Carcinoma Recurrent and remains ongoing. Sponsored by AnewPharma, it has been updated 7 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Nov 2022 — Jul 2024 [monthly]

Unknown Status PHASE1
Jan 2021 — Nov 2022 [monthly]

Unknown Status PHASE1
Feb 2020 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status

▶ Show 2 earlier versions

Jun 2018 — Feb 2020 [monthly]

Recruiting PHASE1
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE1

First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AnewPharma
Peking University Cancer Hospital & Institute

Data source: AnewPharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China